SuperworthAccendra Health profit margin ACH
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- −11.4%
- Operating margin, 12 months
- 1.1%
- Net margin on a year earlier
- +14.0 pts
- Peer median
- 4.9%
Over the twelve months to Jun 30, 2026, Accendra Health kept −11.4% of its revenue as net profit, with an operating margin of 1.1% and a gross margin of 44.8%.
Five years earlier its net margin was 2.5%.
The median for 7 healthcare stocks of a similar size is 4.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −39.8% | 1.0% | 46.7% |
| FY2024 | −5.4% | −3.1% | 26.5% |
| FY2023 | −0.4% | 1.0% | 20.6% |
| FY2022 | 0.2% | 1.4% | 18.3% |
| FY2021 | 2.3% | 3.8% | 15.5% |
| FY2020 | 0.4% | 2.4% | 15.1% |
| FY2019 | −0.7% | 0.8% | 12.3% |
| FY2018 | −4.4% | −4.0% | 13.9% |
| FY2017 | 0.8% | 1.0% | 12.6% |
| FY2016 | 1.1% | 2.1% | 12.2% |
| FY2015 | 1.1% | 2.1% | 12.4% |
| FY2014 | 0.7% | 1.7% | 12.4% |
| FY2013 | 1.2% | 2.2% | 12.3% |
| FY2012 | 1.2% | 2.2% | 10.4% |
| FY2011 | 1.3% | 2.4% | 9.9% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −11.4% | +14.0 pts | 1.1% | |
| Q1 FY26 | −39.8% | −32.1 pts | 0.9% | |
| Q4 FY25 | −39.8% | −34.4 pts | 1.0% | |
| Q3 FY25 | −28.2% | −27.5 pts | −5.4% | |
| Q2 FY25 | −25.4% | −24.9 pts | −5.3% | |
| Q1 FY25 | −7.8% | −7.4 pts | −4.1% | |
| Q4 FY24 | −5.4% | −5.0 pts | −3.1% | |
| Q3 FY24 | −0.7% | +0.4 pts | 1.8% | |
| Q2 FY24 | −0.5% | +0.5 pts | 1.3% | |
| Q1 FY24 | −0.4% | +0.0 pts | 1.0% | |
| Q4 FY23 | −0.4% | −0.6 pts | 1.0% | |
| Q3 FY23 | −1.1% | −2.4 pts | −0.1% |
Against its peers
Companies in Healthcare nearest Accendra Health's size, closest first, today.
| Company | Profit margin |
|---|---|
| ACHAccendra Health | −11.4% |
| NEPHNephros | 8.4% |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 6.8% |
| SPROSpero Therapeutics | 15.7% |
| LFVNLifevantage | 2.8% |
| ICCCImmucell | 2.6% |
| KEQUKewaunee Scientific | 3.0% |
| Peer median | 4.9% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Accendra Health
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.